nach oben

Journal of Neuro-Oncology

Erschienen in:

01.09.2009 | Case Report

Disseminated strongyloidiasis complicating glioblastoma therapy: a case report

verfasst von: Dawit Aregawi, David Lopez, Mark Wick, W. Michael Scheld, David Schiff

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Strongyloides stercoralis is an intestinal parasite that can cause fatal opportunistic infections in immunocompromised patients. Here we report an immunocompromised patient with glioblastoma who developed disseminated strongyloidiasis 6 weeks after completion of standard radiotherapy and concurrent temozolomide chemotherapy. She was effectively treated with albendazole and ivermectin. Strongyloidiasis should be considered in patients being treated for glioma who have lived or traveled to high risk areas and developed gram negative sepsis, along with gastrointestinal or respiratory symptoms, skin rash or SIADH.

Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22(4):610–616. doi:10.1200/JCO.2004.07.060 PubMedCrossRef

Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C et al (2006) Is protracted low-dose temozolomide feasible in glioma patients? Neurology 66(3):427–429. doi:10.1212/01.wnl.0000196465.83423.ec PubMedCrossRef

Hahn BH, MacDermott RP, Jacobs SB, Pletscher LS, Beale MG (1980) Immunosuppressive effects of low doses of glucocorticoids: effects on autologous and allogeneic mixed leukocyte reactions. J Immunol 124(6):2812–2817PubMed

Ganiere V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S et al. (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide. Nat Clin Pract Oncol 3(6):339–343; quiz following 343

Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC et al (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 68(12):955–956. doi:10.1212/01.wnl.0000259430.48835.b5 PubMedCrossRef

Choi JD, Powers CJ, Vredenburgh JJ, Friedman AH, Sampson JH (2008) Cryptococcal meningitis in patients with glioma: a report of two cases. J Neurooncol 89(1):51–53. doi:10.1007/s11060-008-9581-x PubMedCrossRef

Berk SL, Verghese A, Alvarez S, Hall K, Smith B (1987) Clinical and epidemiologic features of strongyloidiasis. A prospective study in rural Tennessee. Arch Intern Med 147(7):1257–1261. doi:10.1001/archinte.147.7.1257 PubMedCrossRef

Zygmunt DJ (1990) Strongyloides stercoralis. Infect Control Hosp Epidemiol 11(9):495–497PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef

10.

Caldenhoven E, Liden J, Wissink S, van de Stolpe A, Raaijmakers J, Koenderman L et al (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9(4):401–412. doi:10.1210/me.9.4.401 PubMedCrossRef

11.

Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G (1992) A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89(21):9991–9995. doi:10.1073/pnas.89.21.9991 PubMedCrossRef

12.

Baus E, Andris F, Dubois PM, Urbain J, Leo O (1996) Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. J Immunol 156(12):4555–4561PubMed

13.

Bischof F, Melms A (1998) Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes. Cell Immunol 187(1):38–44. doi:10.1006/cimm.1998.1308 PubMedCrossRef

14.

Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14(12):436–441. doi:10.1016/0165-6147(93)90184-L PubMedCrossRef

15.

Wilckens T, De Rijk R (1997) Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 18(9):418–424. doi:10.1016/S0167-5699(97)01111-0 PubMedCrossRef

16.

Fardet L, Genereau T, Cabane J, Kettaneh A (2006) Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect 12(10):945–947. doi:10.1111/j.1469-0691.2006.01443.x PubMedCrossRef

17.

Simpson WG, Gerhardstein DC, Thompson JR (1993) Disseminated Strongyloides stercoralis infection. South Med J 86(7):821–825. doi:10.1097/00007611-199307000-00022 PubMedCrossRef

18.

Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB (1981) Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 3(3):397–407PubMed

19.

Genta RM (1992) Dysregulation of strongyloidiasis: a new hypothesis. Clin Microbiol Rev 5(4):345–355PubMed

20.

Thomas MC, Costello SA (1998) Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery. Int J Clin Pract 52(7):520–521PubMed

21.

Link K, Orenstein R (1999) Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J 92(7):728–731. doi:10.1097/00007611-199907000-00016 PubMedCrossRef

22.

Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF (2005) Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 128(5):3681–3684. doi:10.1378/chest.128.5.3681 PubMedCrossRef

23.

Siddiqui AA, Berk SL (2001) Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 33(7):1040–1047. doi:10.1086/322707 PubMedCrossRef

24.

Satoh M, Kokaze A (2004) Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother 5(11):2293–2301. doi:10.1517/14656566.5.11.2293 PubMedCrossRef

25.

Concha R, Harrington W Jr, Rogers AI (2005) Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol 39(3):203–211. doi:10.1097/01.mcg.0000152779.68900.33 PubMedCrossRef

26.

Sato Y, Kobayashi J, Toma H, Shiroma Y (1995) Efficacy of stool examination for detection of strongyloides infection. Am J Trop Med Hyg 53(3):248–250PubMed

27.

Genta RM (1988) Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am J Clin Pathol 89(3):391–394PubMed

28.

Sato Y, Takara M, Otsuru M (1985) Detection of antibodies in strongyloidiasis by enzyme-linked immunosorbent assay (ELISA). Trans R Soc Trop Med Hyg 79(1):51–55. doi:10.1016/0035-9203(85)90233-0 PubMedCrossRef

29.

Hallsworth MP, Litchfield TM, Lee TH (1992) Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils. Immunology 75(2):382–385PubMed

30.

Wallen N, Kita H, Weiler D, Gleich GJ (1991) Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 147(10):3490–3495PubMed

31.

Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC (2004) Complicated and fatal strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 171(5):479–484. doi:10.1503/cmaj.1031698 PubMed

32.

Hughes R, McGuire G (2001) Delayed diagnosis of disseminated strongyloidiasis. Intensive Care Med 27(1):310–312. doi:10.1007/s001340000798 PubMedCrossRef

33.

Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A (2004) Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 35(3):531–534PubMed

34.

Reddy TS, Myers JW (2003) Syndrome of inappropriate secretion of antidiuretic hormone and nonpalpable purpura in a woman with Strongyloides stercoralis hyperinfection. Am J Med Sci 325(5):288–291. doi:10.1097/00000441-200305000-00007 PubMedCrossRef

35.

Seet RC, Gong LL, Tambyath PA (2005) Image of the month. Strongyloides stercoralis hyperinfection and syndrome of inappropriate secretion of antidiuretic hormone. Gastroenterology. 128(1):8, 252

36.

Hayashi E, Ohta N, Yamamoto H (2007) Syndrome of inappropriate secretion of antidiuretic hormone associated with strongyloidiasis. Southeast Asian J Trop Med Public Health 38(2):239–246PubMed

37.

Wachter RM, Burke AM, MacGregor RR (1984) Strongyloides stercoralis hyperinfection masquerading as cerebral vasculitis. Arch Neurol 41(11):1213–1216PubMed

Titel: Disseminated strongyloidiasis complicating glioblastoma therapy: a case report
verfasst von: Dawit Aregawi
David Lopez
Mark Wick
W. Michael Scheld
David Schiff
Publikationsdatum: 01.09.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-9878-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype

An approach to the management of patients with residual Cushing’s disease

Erroneous diagnosis of an intracranial growing teratoma syndrome